Keywords: Lundbeck, PAION, Desmoteplase, Ischemic stroke, Licensing

Lundbeck expands accord with PAION for desmoteplase follow on products

Article | 18 October 2010

Aachen, Germany-based biopharmaceutical company PAION AG (FSE: PA8) has expanded its desmoteplase licence deal with existing partner Denmark’s ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in

Related Companies

Paion

Lundbeck

Go to company listing

Related Drugs

desmoteplase

Go to drug listing